Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials
EF Giunta, G Bregni, A Pretta, A Deleporte… - Cancer treatment …, 2021 - Elsevier
A few months ago, results from two randomised phase III trials of total neoadjuvant therapy
(TNT) in locally advanced rectal cancer were presented (RAPIDO and PRODIGE 23) …
(TNT) in locally advanced rectal cancer were presented (RAPIDO and PRODIGE 23) …
[HTML][HTML] First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE …
Background Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent
therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver …
therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver …
Adjuvant chemotherapy for rectal cancer: current evidence and recommendations for clinical practice
G Bregni, TA Telli, S Camera, A Deleporte… - Cancer treatment …, 2020 - Elsevier
While adjuvant chemotherapy is an established treatment for pathological stage II and
especially stage III colon cancer, its role in the multimodal management of rectal cancer …
especially stage III colon cancer, its role in the multimodal management of rectal cancer …
[HTML][HTML] Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials
N Charette, C Vandeputte, L Ameye, CV Bogaert… - BMC cancer, 2019 - Springer
Background The prognostic value of body composition in cancer patients has been widely
studied during the last decade. The main finding of these studies is that sarcopenia, or …
studied during the last decade. The main finding of these studies is that sarcopenia, or …
Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to …
Background The primary tumor side is emerging as a major prognostic factor for patients
with metastatic colorectal cancer (mCRC). We examined the survival data from 2 …
with metastatic colorectal cancer (mCRC). We examined the survival data from 2 …
Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae
L Plaçais, JM Michot, S Champiat… - Brain …, 2021 - academic.oup.com
Neurological immune-related adverse events are complications of programmed-cell death 1
or programmed-cell death 1 ligand immunotherapies that can be life threatening and often …
or programmed-cell death 1 ligand immunotherapies that can be life threatening and often …
[HTML][HTML] Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor
C Vandeputte, P Kehagias, H El Housni, L Ameye… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Predictive biomarkers are eagerly awaited in advanced colorectal cancer (aCRC). Targeted
sequencing performed on tumor and baseline plasma samples in 20 patients with aCRC …
sequencing performed on tumor and baseline plasma samples in 20 patients with aCRC …
[HTML][HTML] Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology
I Borbath, A Ceratti, C Verslype, A Demols… - Annals of oncology, 2013 - Elsevier
Background Cholangiocarcinomas are uncommon tumours with a poor prognosis, that
frequently present epidermal growth factor receptor overexpression. Methods In a multi …
frequently present epidermal growth factor receptor overexpression. Methods In a multi …
State of the art: radiolabeled microspheres treatment for liver malignancies
A Deleporte, P Flamen, A Hendlisz - Expert opinion on …, 2010 - Taylor & Francis
Importance of the field: Metastatic tumours of the liver are responsible for significant
morbidity and mortality, and only a small percentage is resectable with curative intent …
morbidity and mortality, and only a small percentage is resectable with curative intent …
Fat density is a novel prognostic marker in patients with esophageal cancer
M Anciaux, A Van Gossum, C Wenglinski… - Clinical nutrition …, 2020 - Elsevier
Background & aims While long-term obesity is a well-known risk factor for esophageal
adenocarcinoma (ADC), recent weight loss represents a significant concern in esophageal …
adenocarcinoma (ADC), recent weight loss represents a significant concern in esophageal …